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Precursor mRNA (pre-mRNA) splicing is catalyzed by a large ribonucleoprotein complex known as 
the spliceosome. Numerous studies have indicated that aberrant splicing patterns or mutations in 
spliceosome components, including the splicing factor 3b subunit 1 (SF3B1), are associated with 
hallmark cancer phenotypes. This has led to the identification and development of small molecules 
with spliceosome-modulating activity as potential anticancer agents. Jerantinine A (JA) is a novel 
indole alkaloid which displays potent anti-proliferative activities against human cancer cell lines by 
inhibiting tubulin polymerization and inducing G2/M cell cycle arrest. Using a combined pooled-genome 
wide shRNA library screen and global proteomic profiling, we showed that JA targets the spliceosome 
by up-regulating SF3B1 and SF3B3 protein in breast cancer cells. Notably, JA induced significant 
tumor-specific cell death and a significant increase in unspliced pre-mRNAs. In contrast, depletion of 
endogenous SF3B1 abrogated the apoptotic effects, but not the G2/M cell cycle arrest induced by JA. 
Further analyses showed that JA stabilizes endogenous SF3B1 protein in breast cancer cells and induced 
dissociation of the protein from the nucleosome complex. Together, these results demonstrate that 
JA exerts its antitumor activity by targeting SF3B1 and SF3B3 in addition to its reported targeting of 
tubulin polymerization.
Precursor mRNA (pre-mRNA) splicing is a fundamental process in eukaryotic cells, which is catalyzed by the 
spliceosome, a macromolecular ribonucleoprotein (RNP) complex composed of five small nuclear ribonucleo-
proteins (U1, U2, U4, U5 and U6 snRNPs) and more than 200 polypeptides1–3. The splicing factor 3b subunit 1 
(SF3B1) protein is a core component of the U2 snRNP at the catalytic center of the spliceosome, which recognizes 
and defines the 3′ splice site at the intron-exon junctions4.
Through pre-mRNA splicing, a single pre-mRNA transcript may give rise to multiple different combinations 
of introns and exons, resulting in increased transcript diversity and the synthesis of alternative proteins5. While 
changes in alternative splicing patterns play an integral role in normal development and cell differentiation, 
numerous cancer-specific aberrant splicing patterns have been documented6,7. However, it is currently unclear 
whether the observed splicing abnormalities are a by-product of cellular transformation or an intrinsic charac-
teristic of transformed cells.
Recently, growing evidence has demonstrated that aberrant splicing contributes to essential pheno-
types associated with transformed cells. For instance, alternative protein products of epidermal growth factor 
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receptor (EGFR)8, p539, vascular endothelial growth factor (VEGF)10, and E-cadherin11 reportedly promoted 
cancer-associated pathways, including the evasion of apoptosis, increased cell proliferation, angiogenesis, and 
invasion. Mutations in SF3B1 have also been reported in myelodysplastic syndromes (MDS) as well as numerous 
cancers, including acute myeloid leukemia, primary myelofibrosis, chronic myelomonocytic leukemia (CML)12, 
chronic lymphocytic leukemia (CLL)13,14, multiple myeloma, uveal melanoma15–18 and breast cancers19–21. While 
it is currently unclear as to how SF3B1 mutations might alter its function, previous studies have shown that the 
dysregulation of spliceosomal components can alter splicing patterns, causing intron retention or exon skip-
ping, and affect protein isoform balances leading to abnormal cell proliferation or differentiation2,22. As such, 
the spliceosome has emerged as an attractive target for anticancer treatment. Several spliceosome modulators 
have already been identified, including natural products derived from bacterial fermentation (e.g. pladienolides, 
GEX1, FR901463, etc.) and their synthetic analogues (spliceostatin A, meayamycin and E7107) as well as natural 
plant products (e.g. isoginkgetin)23.
Indole alkaloids represent a large and highly structurally diverse group of secondary metabolites with remark-
able bioactivities against the different targets in cancer. The importance of this group of compounds is best 
represented by the Vinca alkaloid vinblastine, which is currently among the foremost drugs used in cancer chemo-
therapy24. Previously, we have described the potent and selective antitumor activity of seven new Aspidosperma 
indole alkaloids, jerantinines A-G, isolated from the leaf extracts of the Malayan plant Tabernaemontana corymbosa 
(Fig. 1A)25. Jerantinines A-E were found to display pronounced in vitro anti-proliferative activities against human 
cancer cell lines in the nanomolar range26–28. Furthermore, we have recently demonstrated that jerantinine A and 
B and the acetate derivative inhibited tubulin polymerization, polo-like kinase 1 (PLK1) activity and induced 
G2/M cell cycle arrest in a panel of human cancer cell lines consisting of vincristine-resistant nasopharyngeal 
carcinoma cells25, as well as breast, colorectal, lung and pancreatic carcinoma cells27,28. Similarly, jerantinine E 
was also shown to disrupt microtubules, and displayed significant antitumor activity against human cervical 
carcinoma cells29. Importantly, no cross-resistance to jerantinines was observed in vincristine-resistant HCT-116 
cells, suggesting that jerantinines overcome p-glycoprotein-mediated multidrug resistance and might affect other 
cancer-relevant targets besides tubulin25,27,28.
Using a pooled-genome wide shRNA library screen and global proteomic profiling, we demonstrated that 
jerantinine A (JA) targets the cancer spliceosome through the upregulation of SF3B1 and SF3B3 proteins in breast 
cancer cells. Importantly, ectopic expression of SF3B1, SF3B3 or JA treatment induced significant tumor-specific 
cell death accompanied by the accumulation of unspliced pre-mRNAs. In contrast, the depletion of endogenous 
SF3B1 or SF3B3 abrogated the apoptotic effects induced by JA, but not the G2/M cell cycle arrest. Further analyses 
revealed that JA stabilizes endogenous SF3B1 protein and disrupts the binding of the protein to the nucleosome 
complex in breast cancer cells. Together, our results suggest that JA exerts its antitumor activity by targeting 
SF3B1 in addition to its reported targeting of tubulin polymerization.
Results
Jerantinine A induces tumor-specific cell death in breast cancer cell lines. To test the selective 
antitumor activity of JA, we compared its anti-proliferative activities in a panel of breast cancer cell lines consist-
ing of estrogen receptor (ER)-positive (MCF-7 and T47D) and triple-negative cells (MDA-MB-468). As shown in 
Fig. 1B and Supplementary Table S1, JA elicits activity against all the breast cancer cell lines being tested (approx. 
IC50 = 1 μ M), while the non-transformed MCF-10A cells were relatively resistant (IC50 > 10 μ M). Similarly, apop-
totic morphological changes were also observed in JA-treated cancer cells, but no such changes were observed 
in non-transformed cells (Fig. 1C). The effects of JA on cell cycle arrest and cell death were further investigated 
by propidium iodide staining and annexin V/7-AAD flow cytometry analysis, respectively. Consistent with our 
previous reports, JA induced significant G2/M arrest in MCF-7 cells (19% in control cells vs 64% in JA-treated 
cells, Supplementary Fig. S1A)27,28. The percentage of apoptotic cells in MCF-7 and MDA-MB-468 cells after JA 
treatment was also significantly higher than in the control cells (P < 0.01, Student’s t-test; Fig. 1D). However, no 
significant induction of caspase 3/7, 8 and 9 activities were detected in response to JA treatment, suggesting that 
JA might induce caspase-independent apoptosis (Supplementary Fig. S1B). Of note, the induction of apoptosis 
was observed as early as 6 h after treatment, suggesting that JA might target endogenous proteins rather than 
transcriptional activation.
Proteomic profiling of MCF-7 breast cancer cells following JA treatment. We have previously 
demonstrated that jerantinine A and B inhibited tubulin polymerization, PLK1 activity and induced G2/M 
cell cycle arrest in a panel of human cancer cell lines27,28. Importantly, no cross-resistance to jerantinine A and 
B was observed in vincristine-resistant cancer cells, suggesting that jerantinine A and B might affect other 
cancer-relevant targets in addition to tubulin. To systematically identify molecular targets involved in modulating 
the antitumor activity of JA, we carried out a combined proteomic-RNAi screen. We hypothesized that direct tar-
gets mediating the antitumor activities of JA should have two properties: 1) they should be differentially expressed 
following JA treatment, and 2) they should be functionally required to sustain the antitumor activity of JA.
To identify proteins that are differentially regulated in JA-treated MCF-7 cells, we conducted a global 
proteomic analysis using multidimensional protein identification technology (MudPIT) (Fig. 2A and 
Supplementary Fig. S2A). We identified 509 up-regulated proteins (Supplementary Table S2) and 429 
down-regulated proteins (Supplementary Table S3). Among them were proteins that are involved in assembly of 
the spliceosome, cellular metabolism, endocytosis and axon guidance (Supplementary Fig. S2B). Of note, several 
proteins that are associated with mitosis (e.g. ANAPC7, MCM3, MCM7, SMC2, SMC3, TUBG1 and TUBG2) 
and apoptosis (e.g. FADD and DIABLO) were also found to be up-regulated, consistent with the phenotype we 
observed previously27,28.
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Genome-wide shRNA functional screen identifies a compendium of genes affecting sensitivity 
to JA. In a parallel RNAi screen, we used the same cell line used for the proteomic profiling to identify genes 
that were functionally required for JA activity. We treated the pooled genome-wide shRNA transduced cells for 
72 h with JA, isolated the genomic DNA and analyzed the abundance of shRNA by next-generation sequencing 
(NGS). Conceptually, the shRNAs that are “enriched” (Z-scores > 2) in the surviving cell population are genes 
that are essential for eliciting the killing response caused by JA since silencing the gene prevents the cell-death 
signal from propagating. Thus, analysis of the “enriched” shRNAs indicates which genes are necessary for the 
Figure 1. JA induces tumor-specific cell death in breast cancer cell lines. (A) Chemical structure of JA. 
(B) Growth inhibitory effects of JA on breast cancer cells. MCF-7, and MDA-MB-468 breast cancer cell lines, 
as well as the non-transformed MCF-10A breast cell line, were treated with increasing concentrations of 
JA. Cell viability was determined using the MTT cell viability assay 72 h after JA treatment. Each data point 
represents the mean ± s.d. of at least 3 independent experiments. (C) Morphological changes at 24 h following 
JA treatment in MCF-7, MDA-MB-468, and MCF-10A cells. Original magnification, x100. (D) JA induced 
time-dependent apoptosis in MCF-7 and MDA-MB-468 cells. Cells were treated with 1 μ M of JA followed by 
quantitation of apoptosis at various time points using annexin V/7-AAD flow cytometry. Bars represent the 
means ± s.d. of 3 independent experiments. Asterisks (*) indicate statistical significance compared with vehicle 
cells (P < 0.01, Student’s t-test).
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Figure 2. Combined proteomic-RNAi screen analyses revealed spliceosome as putative target of JA. 
(A) Design of the combined proteomic profiling and genome-wide shRNA screen to identify new molecular 
targets of JA. MCF-7 cells were treated with 1 μ M of JA for 8 h and their protein lysate were isolated for global 
proteomic analysis by MudPIT (left). Genes that were required for JA activities were identified by pooled 
genome-wide shRNA screen and NGS analysis following treatment of MCF-7 cells with 1 μ M of JA for 72 h 
(right). The intersection of the data generated 28 candidate targets that were required for JA activities and were 
up-regulated in JA-treated cells. (B) DAVID enrichment analysis showing JA target genes associated with the 
spliceosome pathway (KEGG pathway, P < 0.01). (C) Protein-protein interaction network of the JA target 
proteins. Networks were generated with STRING at the highest confidence threshold (0.9). Note the seven 
interacting targets (SF3B1, SF3B3, SNRPA, SNRPE, SNRPF, HNRNPA3 and EFTUD2) are proteins within the 
spliceosome complex.
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lethal activity of JA. Vice versa, shRNAs that make cells more susceptible to JA treatment would be “depleted” in 
the surviving cell population, indicating that these genes might help cells survive in the presence of JA. Hence, 
inhibiting the function of these genes might sensitize the antitumor effects of JA.
Following this screen, a total of 381 candidate genes that were enriched in JA-treated cells and 121 candidate 
genes that were depleted in JA-treated cells were identified (Fig. 2A and Supplementary Fig. S3A,B). Among 
the shRNAs that were highly enriched in JA-treated cells are genes that are involved in the human spliceosome, 
cell metabolic pathways, the neurotrophin pathway and the MAPK signaling pathway (Supplementary Fig. S3C 
and Supplementary Table S4). Interestingly, shRNAs targeting genes that are involved in calcium signaling 
(e.g. P2RX1, PDE1C, TACR1, NOS3 and ITPR2), autophagy (e.g. ATG4A and ATG4C) and the estrogen sig-
naling pathway (e.g. ITPR2, CREB3L2, NOS3 and SOS2) were found to be depleted in the surviving cells, sug-
gesting that the inhibition of these pathways in combination with JA treatment may evoke a synergistic response 
(Supplementary Fig. S3C and Supplementary Table S5).
Combined functional genomic and proteomic approaches identify the cancer spliceosome as 
a putative target of JA. Next we ‘intersected’ the proteomic data set with the RNAi screen data set. In the 
intersection, we found 28 targets that were required for JA activity and were induced in JA-treated cells (Fig. 2A 
and Supplementary Table S6). Among these targets was the Fas-associated via death domain (FADD) which is 
known to regulate apoptosis and necroptosis30, and glycogen synthase kinase 3 beta (GSK3B), which has been 
shown to function in a wide range of cellular processes and signaling pathways including suppression of the Wnt/
beta-catenin pathway31. Functional enrichment analysis was carried out using the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database to classify the candidate targets into statistically significant over-represented 
functional categories. The genes involved in the spliceosome were significantly over-represented (P < 0.01, 
Fig. 2B). To further investigate the mechanism of action of JA, the 28 candidate targets were mapped onto 
protein-protein interaction networks using STRING32. Interestingly, the analysis revealed that 7 targets (SF3B1, 
SF3B3, SNRPA, SNRPE, SNRPF, HNRNPA3 and EFTUD2) are physically interacting proteins within the spli-
ceosome complex, suggesting that JA might regulate the cancer spliceosome to induce tumor-specific cell death 
(Fig. 2C).
JA triggers dysregulation of SF3B1 and SF3B3 proteins. To validate whether JA regulates the cancer 
spliceosome, we carried out immunoblotting to confirm the expression of SF3B1 and SF3B3 following JA treat-
ment in MCF-7 and MDA-MB-468 cells. As shown in Fig. 3A, JA induced a time-dependent increase in cellular 
SF3B1 and SF3B3 proteins, consistent with the results obtained from the MudPIT analysis. Of note, the induc-
tion of SF3B1 and SF3B3 was observed as early as 6 h after treatment, which corroborated with the induction of 
apoptosis (Fig. 1D). Interestingly, no significant changes in mRNA levels of the SF3B family in response to JA 
were detected (Supplementary Fig. S4A), suggesting that the induction of protein expression is independent of 
transcriptional activity. Further analyses after the cycloheximide chase assay revealed that JA markedly prolonged 
the life-span of the SF3B1 protein in both MCF-7 and MDA-MB-468 cells, suggesting that JA regulates SF3B1 
protein stability rather than transcriptional activation (Supplementary Fig. S4B,C). In contrast to the breast can-
cer cells, both SF3B1 and SF3B3 were found to be down-regulated by JA in the non-transformed MCF-10A cells 
(Supplementary Fig. S5A).
JA induces pre-mRNA splicing errors. As previous studies have demonstrated that anticancer 
spliceosome-targeting compounds such as pladienolides and sudemycin inhibit splicing activity33–35, we 
sought to evaluate the effect of JA on splicing activity by quantifying the amounts of unspliced pre-mRNA of 
RIOK3, CDKN1B, DNAJB1, and BRD2 by qPCR using primer sets specific for the intronic regions as described 
previously33,35. We observed that JA treatment resulted in a significant increase in unspliced pre-mRNA 
in MCF-7 and MDA-MB-468 cells, indicating that JA significantly impairs splicing activity (Fig. 3B and 
Supplementary Fig. S6A). In contrast, the amounts of unspliced pre-mRNA of RIOK3 and CDKN1B were signif-
icantly lower in MCF-10A cells treated with JA (Supplementary Fig. S5B), corroborating the down-regulation of 
SF3B1 and SF3B3 in these cells (Supplementary Fig. S5A). Of note, no significant changes in the levels of spliced 
mRNA was observed in cells following JA treatment (Supplemental Figs S5B and S6B).
Induction of SF3B1 impairs pre-mRNA splicing and induces apoptosis in breast cancer 
cells. Since SF3B1 and SF3B3 have been shown to be a core component of the U2 snRNP of the spliceosome 
and is essential in regulating pre-mRNA splicing in cancer cells4, we hypothesize that the dysregulation of SF3B1 
and/or SF3B3 (activation and inhibition) might result in the loss of critical proteins and the expression of variants 
with aberrant function that influence the survival of cancer cells.
To test whether SF3B1 and SF3B3 upregulation alone would trigger apoptosis and perturb splicing activity, 
SF3B1 and SF3B3 was transiently overexpressed in MCF-7 and MDA-MB-468 (Fig. 4A,B). Indeed, we observed 
that SF3B1 and SF3B3 overexpression induced significant apoptosis (Fig. 4C,D). Similarly, overexpression of 
SF3B1 also inhibited splicing activity in both cell lines, analogous to the phenotype induced by JA (Fig. 4E). In 
contrast, the splicing of RIOK3, CDKN1B, DNAJB1, and BRD2 remained unchanged in SF3B3 overexpressed 
cells (Fig. 4F).
SF3B1 and SF3B3 are required for the antitumor effects of JA. Next, we investigated whether SF3B1 
or SF3B3 mediate the antitumor activity of JA. We generated a stable pool of isogenic cells depleted for SF3B1 
or SF3B3 by the transduction of two independent lentiviral shRNA constructs targeting the endogenous pro-
teins in MCF-7 and MDA-MB-468 cells, followed by brief drug selection with puromycin. Indeed, depletion 
of SF3B1 or SF3B3 partially rescued the apoptotic cell death induced by JA in both MCF-7 and MDA-MB-468 
cells (Fig. 5A–D). Furthermore, double knock-down of SF3B1 and SF3B3 completely abrogated the apoptotic 
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effects of JA, suggesting that both SF3B1 and SF3B3 are required for the antitumor effects of JA (Fig. 5E,F). Also, 
knock-down of SF3B1, but not SF3B3, significantly reduced the accumulation of unspliced pre-mRNA induced 
by JA (Supplementary Fig. S7), suggesting that the mis-splicing of RIOK3, CDKN1B, BRD2 or DNAJB1 following 
JA treatment is dependent on SF3B1 but not SF3B3. SF3B1 depletion, however, did not rescue the G2/M cell cycle 
arrest induced by JA treatment (Supplementary Fig. S8), indicating that SF3B1 is dispensable for the cytostatic 
effects of JA, but more critical for apoptosis execution.
JA disrupts the interactions of SF3B1 and SF3B3 in the nucleosome complexes. A recent study 
has shown that SF3B1 is associated with the nucleosome complexes and affects splicing outcomes36. To evaluate 
whether the association of SF3B1 and SF3B3 in the nucleosome complexes might be affected by JA, we performed 
co-immunoprecipitation (co-IP) assays in MCF-7 cells treated with JA for 24 h. Our results indicated a strong 
association of SF3B1 and SF3B3 with H2B and H3 in the nucleosome (Fig. 6). However, such associations were 
Figure 3. JA induces SF3B1 and SF3B3 protein expression and induces mRNA splicing errors. (A) MCF-7 
and MDA-MB-468 cells were treated with 1 μ M of JA for 6, 12, 24 and 48 h, followed by immunoblotting 
analyses. Increased accumulation of SF3B1 and SF3B3 was detected following treatment with JA. Cropped blot 
is shown from one representative experiment. Full-length gels are included in the Supplementary information 
file. (B) JA induced mRNA splicing errors in MCF-7 and MDA-MB-468 cells. Cells were treated with 1 μ M of JA 
for 6, 12, 24 and 48 h. Unspliced pre-mRNA was quantified using qPCR targeting the intronic regions of RIOK3, 
CDKN1B, DNAJB1, and BRD2. Bars represent the means ± s.d. of at least 3 independent experiments. Asterisks 
(*) indicate statistical significance compared with vehicle cells (P < 0.01, Student’s t-test). Note the significant 
induction of protein and unspliced pre-mRNA in JA-treated cells as early as 6 h after treatment.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:42504 | DOI: 10.1038/srep42504
diminished following treatment of cells with JA. These results suggest that JA disrupts the interactions of SF3B1 
and SF3B3 with the nucleosome. Together, our results demonstrated that JA exerts its antitumor activity in cancer 
cells at least in part by targeting SFB1 (and SFB3).
Figure 4. Overexpression of SF3B1 and SF3B3 induces splicing errors and tumor-specific apoptosis. (A and B) 
SF3B1 and SF3B3 were transiently overexpressed in MCF-7 and MDA-MB-468 cells. Cropped blot is shown from 
one representative experiment. Full-length gels are included in the Supplementary information file. (C and D) 
Ectopic SF3B1 and SF3B3 expression induced significant apoptosis. (E and F) Ectopic expression of SF3B1, but not 
SF3B3, induced unspliced RIOK3, CDKN1B, DNAJB1, and BRD2 pre-mRNA expression. Asterisks (*) indicate 
statistical significance compared with control cells transfected with the empty vector (P < 0.01, Student’s t-test).
www.nature.com/scientificreports/
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Figure 5. The antitumor activity of JA is mediated by SF3B1 and SF3B3. (A–D) A stable pool of isogenic 
cells depleted for SF3B1 or SF3B3 was generated in MCF-7 and MDA-MB-468 cells using two independent 
lentiviral shRNA constructs targeting the endogenous proteins, followed by brief puromycin selection. Levels 
of knock-down were evaluated by immunoblotting. SF3B1 or SF3B3 depleted cells were treated with 1 μ M of 
JA. Apoptosis was evaluated at 72 h after treatment. Cropped blot is shown from one representative experiment. 
Full-length gels are included in the Supplementary information file. Bars represent the means ± s.d. of 3 
independent experiments. Asterisks (*) indicate statistical significance compared with control cells without 
JA treatment (P < 0.01, Student’s t-test). Vec, vector control cells. NS, non-targeting shRNA. (E and F) 
Simultaneous knock-down of SF3B1 and SF3B3 completely abrogated the apoptotic effects of JA. MCF-7 cells 
were transfected with SF3B1si-1 and/or SF3B3si-1 for 48 h followed by JA treatment for 24 h. Cropped blot is 
shown from one representative experiment. Full-length gels are included in the Supplementary information 
file. Asterisks (*) indicate statistical significance compared with control cells without JA treatment (P < 0.01, 
Student’s t-test). Hash (#) indicates statistical significance compared to SF3B1- or SF3B3-depleted cells 
following treatment with JA (P < 0.01, Student’s t-test).
www.nature.com/scientificreports/
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Discussion
The spliceosome represents an under-explored and unusual target in cancer cells. The recent identification of 
small molecules (e.g. Spliceostatin, Sudemycins and Pladienolides) that interact with SF3B1, and the identifica-
tion of mutant SF3B1 in tumor samples indicate that this complex can be a viable target for chemotherapeutic 
intervention2,3. While the exact mechanism of cytotoxicity induced by these spliceosome modulators is currently 
unclear, evidence indicates that interaction with SF3B1 is crucial for their antitumor activity2,3.
JA is an anticancer compound that has been previously reported by our group to possess remarkable antitu-
mor activities27,28. Using combined proteomic and functional genomics analyses, we identified SF3B1 and SF3B3 
as putative targets of JA. However, unlike other spliceosome modulators which have been shown to inhibit SF3B1, 
JA was found to induce SF3B1 and SF3B3 protein expression through increased protein stability. Intriguingly, the 
induction of SF3B1 by JA or ectopic expression of SF3B1 in MCF-7 and MDA-MB-468 cells impairs mRNA splic-
ing activity as evidenced by the accumulation of unspliced RIOK3, CDKN1B, DNAJB1 and BRD2 pre-mRNA. 
In contrast, the amounts of unspliced pre-mRNA remained unchanged following ectopic expression of SF3B3 
in MCF-7 and MDA-MB-468 cells, despite observation of significant apoptotic cell death. Of note, depletion 
of the endogenous SF3B1 or SF3B3 partially inhibited the apoptosis induced by JA in breast cancer cells, while 
the simultaneous knock-down of SF3B1 and SF3B3 completely abrogated the apoptotic effects of JA, suggesting 
that both SF3B1 and SF3B3 are required for the antitumor activity of JA in breast cancer cells. However, only 
knock-down of SF3B1, but not SF3B3, significantly reduced the accumulation of unspliced pre-mRNA following 
JA treatment indicating that the mis-splicing of RIOK3, CDKN1B, BRD2 or DNAJB1 following JA treatment is 
dependent on SF3B1 but not SF3B3. These results suggest that SF3B1 and SF3B3 might induce tumor specific cell 
death through distinct mechanisms. Indeed, SF3B3 has been recently shown to regulate alternative splicing of 
EZH2 pre-mRNA in renal cancer and mediates ubiquitination through modulation of the NEDD8 pathway37,38.
Numerous studies have also demonstrated that overexpression and mutations of key spliceosome components 
are associated with malignancies in various tissues, resulting in aberrant splicing activity and the emergence of 
hallmark cancer phenotypes3,6,23,39–41. Alterations in SF3B1 have been reported in myelodysplastic syndromes 
(~20%)19,42,43, acute myeloid leukemia (~5%)19, chronic lymphocytic leukemia (~5%)12,19 and other solid tumors 
including breast cancer (~1%)19–21, renal cancer (~3%)19 and adenoid cystic carcinoma (~4%)19. In breast can-
cer, in particular, SF3B1 mutations were significantly associated with ER-positive disease, AKT1 mutations, and 
distinct copy number alterations20. While the potential function of SF3B1 mutants has yet to be fully elucidated, 
the spliceosome modulator, spliceostatin A, was found to be more potent in cell lines harboring SF3B1 muta-
tions compared to SF3B1 wild-type cells20. This, however, was not observed in the JA-treated cells, as the SF3B1 
wild-type MDA-MB-468, T47D and MCF7 cells are equally sensitive to JA as compared to the HCC38 cells, 
which harbors a heterozygous SF3B1 Q534P missense mutation (data not shown)44. This result suggests that the 
antitumor effect of JA is independent of SF3B1 mutations.
It is intriguing to investigate how the dysregulation of SF3B1, via either activation or inhibition, could 
lead to tumor-specific cell death. It is known that the maintenance of high-fidelity mRNA splicing is impor-
tant, because the translation of mis-spliced mRNAs into proteins with aberrant function could be deleterious 
to all cells. Therefore, it is not surprising that eukaryotic cells have evolved a protective mechanism, known as 
nonsense-mediated decay (NMD), to target and eliminate the inappropriately spliced mRNAs45. Interestingly, 
several pathways involved in NMD were recently found to be inactivated in many cancers including breast, colon, 
Figure 6. JA disrupts the interactions of SF3B1 and SF3B3 with histone H2B and H3 in the nucleosome 
complexes. MCF-7 cells were treated with 1 μ M of JA for 24 h. Immunoprecipitation was performed with 
antibodies against SF3B1, SF3B3 or non-specific IgG. Western blotting was performed with the indicated 
antibodies. The heavy chain (HC) of the IgG served as loading control. Cropped blot is shown from one 
representative experiment. Full-length gels are included in the Supplementary information file.
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liver, lung, thyroid and esophagus cancer46. Although it is currently unclear whether JA sensitivity is dependent 
on NMD deficiency, a recent study showed that NMD efficiency in MCF-7 cells, which are sensitive to JA, was 
significantly lower compared to HeLa cells47. Similarly, siRNA-mediated depletion of SNRPE or SNRPD1, com-
ponents of the core spliceosomal heteroheptameric Sm complex, also led to a marked reduction of cell viability in 
MDA-MB-468 and SKBR3 breast cancer cells, but not in the non-tumoral MCF-10A cells48. Thus, it is plausible 
that the dysregulation of SF3B1 and spliceosome activity by JA might lead to an imbalance in the splicing pro-
gram in susceptible cancer cells, which may induce apoptosis by the accumulation of mis-spliced mRNAs into 
deleterious proteins.
While most spliceosome modulators vary greatly in terms of chemical structure, they have all been shown to 
have almost identical effects on spliceosome assembly49,50. A recent study has demonstrated that spliceostatin A, 
pladienolide B and herboxidiene all interact with the same site on SF3B1, and likely exhibit the same mechanism 
of action of inhibiting spliceosome assembly, possibly by interfering with SF3B1 conformational states50. Also, 
unlike the splicing modulator sudemycin which was recently shown to induce a specific antitumor response in 
chronic lymphocytic leukemia through alternative splicing of MCL1 to generate its proapoptotic isoform51, no 
such effect was observed in MCF-7 and MDA-MB-468 treated with JA (Supplementary Fig. S9). Whether JA 
interacts with SF3B1 in a similar manner to that of the aforementioned spliceosome modulators remains to be 
further investigated. However, based on the distinct mechanism of JA in stabilizing SF3B1, rather than inhibition 
as demonstrated by other spliceosome modulators, it is likely that JA might engage a novel mechanism to regulate 
the cancer spliceosome activities. Hence, further understanding of how JA might interact with SF3B1 will be 
invaluable for the design and further development of new drug candidates.
In conclusion, our findings indicate that JA evokes tumor-specific activity by targeting SF3B1 and causing 
abnormal splicing patterns, in addition to its previously reported activity of inhibiting microtubule polymeriza-
tion. While the precise mechanism by which JA inhibits splicing activity has yet to be elucidated, the fact that it is 
multi-targeted as well as tumor-specific makes it an attractive candidate for further development. More compre-
hensive understanding of these mechanisms, coupled with knowledge of the spliceosome functions in tumors are 
important for the further development of this novel class of experimental antitumor agents.
Methods
Chemicals and reagents. Jerantinine A was isolated from the leaf ethanolic extract of the Malayan 
Tabernaemontana corymbosa Roxb. ex Wall and characterized as reported previously25.
Cell lines and cell culture. The human breast cancer cell lines (MDA-MB-468, T47D and MCF7) were 
obtained from American Type Culture Collection (ATCC) and were maintained in RPMI-1640 medium con-
taining 10% fetal bovine serum (FBS), 100 IU/ml of penicillin, and 100 μ g/ml of streptomycin (Sigma-Aldrich, St. 
Louis, MO, USA). The non-transformed human mammary epithelial cell line MCF-10A was cultured in DMEM/
F12 (Invitrogen, Carlsbad, CA, USA) supplemented with 5% horse serum, 20 ng/ml epidermal growth factor 
(EGF), 0.5 μ g/ml hydrocortisone, 10 μ g/ml insulin, 100 IU/ml penicillin, and 100 μ g/ml streptomycin. All cells 
were maintained at 37 °C in 5% CO2. Cells were passaged for less than 6 months and no further authentication 
was performed by the authors.
Cell proliferation assay. Dose-response curves and IC50 values were determined using the 3-(4,5-dime
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay, as described previously52,53.
Flow cytometric detection of apoptosis. The population of apoptotic cells was quantified using the 
PE Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s 
instructions. Both floating and attached cells were collected, stained, and analyzed using a FACSCalibur flow 
cytometer and the CellQuest Pro software (version 5.1.1; BD Biosciences, USA).
Proteomic profiling. MCF-7 cells were treated with vehicle or 1 μ M of JA for 8 h. Cells were harvested using 
a cell lifter and washed twice with phosphate buffer saline (PBS). LC–MS/MS analysis was performed as a service 
by Bioproximity LLC (Chantilly, VA, USA).
Pooled genome-wide shRNA library screen. MCF-7 cells were transduced with MISSION LentiPlex 
Human Pooled shRNA Library, targeting more than 15000 human genes (Sigma-Aldrich, USA). Tranduced 
cells were selected with 1 μ g/mL puromycin for 4 days and treated with vehicle or 1 μ M of JA for 72 h. Genomic 
DNA was isolated using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma, USA) according to 
the manufacturer’s protocol. shRNA sequences present in each sample were determined by next-generation 
sequencing (NGS). Massively parallel sequencing for shRNA retrieval and screen data analysis were described in 
Supplementary Methods.
Quantitative real-time PCR analysis. mRNA expression levels were measured by real-time quan-
titative PCR (qPCR) as described previously54,55. Briefly, total cellular RNA was extracted using the Qiagen 
RNA Isolation Kit (Qiagen, Valencia, CA, USA). First-strand cDNA was synthesized using the High Capacity 
RNA-to-cDNA Master Mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instruc-
tions. Gene expression levels were measured by qPCR using the FastStart Universal SYBR Green Master (Roche 
Diagnostics, Indianapolis, IN, USA) and a Biorad iQ5 real-time PCR detector system (Bio-Rad, Hercules, CA, 
USA). Spliceosome activity was estimated by amplification of the intronic regions of DNAJB1, CDKN1B, RIOK3 
and BRD2, as described previously51,56,57. qPCR conditions for all amplifications are as follows: 3 min at 94 °C fol-
lowed by 40 cycles of 94 °C for 40 sec, 60 °C for 40 sec, and 72 °C for 25 sec. Gene expression data were normalized 
to GAPDH as the house-keeping gene. The specific primers are shown in Supplementary Table S7.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7:42504 | DOI: 10.1038/srep42504
Transfection. The SF3B1 and SF3B3 expression construct was obtained from OriGene Technologies 
(Rockville, MD, USA). Transient transfections were performed using X-tremeGENE HP DNA transfection rea-
gent (Roche Diagnostics, USA) according to the manufacturer’s instructions.
Lentivirus production and transduction. Lentiviral non-targeting shRNA (NS) and shRNA constructs 
targeting SF3B1 and SF3B3 were purchased from Sigma-Aldrich (St. Louis, MO, USA). The shRNAs target 
sequences were presented in Supplementary Table S8. Lentivirus production and transduction were performed 
as described previously52,54. Briefly, high-titer lentiviral stocks were generated by co-transfection with packaging 
plasmids psPAX2 (Addgene plasmid #12260) and envelope plasmids pMD2.G (Addgene plasmid #12259) into 
HEK-293T using CalPhos Transfection Kits (Clontech, Mountain View, CA, USA). Supernatants containing len-
tiviral stocks were supplemented with polybrene (Sigma, USA) and used for transduction of target cells. Stable 
pools were generated by transduction of two independent lentiviral shRNA constructs targeting SF3B1 followed 
by brief selection with puromycin (Sigma, USA).
Protein isolation and immunoblotting. Protein lysates were extracted using ice-cold lysis buffer 
(1% NP-40, 1 mM DTT, supplemented with protease and phosphatase inhibitors in PBS). Total protein (50 μ g) 
was subjected to SDS-PAGE followed by immunoblotting. Primary antibodies against SF3B1 and SF3B3 were 
obtained from Antibodies-online GmbH (Aachen, Germany). Mouse monoclonal antibodies against β -actin 
(clone C-2; 1:250) and GAPDH (G-9; 1:1,000) were obtained from Santa Cruz Biotechnology (Dallas, Texas, 
USA). Rabbit monoclonal antibodies against histone H2B and histone H3 were purchased from Cell Signaling 
Technology (Danvers, MA, USA).
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